243 related articles for article (PubMed ID: 35188645)
1. Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing.
Arnesdotter E; Gijbels E; Dos Santos Rodrigues B; Vilas-Boas V; Vinken M
Methods Mol Biol; 2022; 2425():521-535. PubMed ID: 35188645
[TBL] [Abstract][Full Text] [Related]
2. Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.
Vinken M
Methods Mol Biol; 2016; 1425():325-37. PubMed ID: 27311472
[TBL] [Abstract][Full Text] [Related]
3. The adverse outcome pathway concept: a pragmatic tool in toxicology.
Vinken M
Toxicology; 2013 Oct; 312():158-65. PubMed ID: 23978457
[TBL] [Abstract][Full Text] [Related]
4. Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach.
van Ertvelde J; Verhoeven A; Maerten A; Cooreman A; Santos Rodrigues BD; Sanz-Serrano J; Mihajlovic M; Tripodi I; Teunis M; Jover R; Luechtefeld T; Vanhaecke T; Jiang J; Vinken M
J Biomed Inform; 2023 Sep; 145():104465. PubMed ID: 37541407
[TBL] [Abstract][Full Text] [Related]
5. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.
Halappanavar S; van den Brule S; Nymark P; Gaté L; Seidel C; Valentino S; Zhernovkov V; Høgh Danielsen P; De Vizcaya A; Wolff H; Stöger T; Boyadziev A; Poulsen SS; Sørli JB; Vogel U
Part Fibre Toxicol; 2020 May; 17(1):16. PubMed ID: 32450889
[TBL] [Abstract][Full Text] [Related]
6. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
[TBL] [Abstract][Full Text] [Related]
7. Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury.
Gijbels E; Vilas-Boas V; Annaert P; Vanhaecke T; Devisscher L; Vinken M
Arch Toxicol; 2020 Apr; 94(4):1151-1172. PubMed ID: 32152650
[TBL] [Abstract][Full Text] [Related]
8. Adverse outcome pathway development from protein alkylation to liver fibrosis.
Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
[TBL] [Abstract][Full Text] [Related]
9. Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways.
Clerbaux LA; Filipovska J; Nymark P; Chauhan V; Sewald K; Alb M; Sachana M; Beronius A; Amorim MJ; Wittwehr C
ALTEX; 2024; 41(2):233-247. PubMed ID: 37980615
[TBL] [Abstract][Full Text] [Related]
10. Semantic characterization of adverse outcome pathways.
Wang RL
Aquat Toxicol; 2020 May; 222():105478. PubMed ID: 32278258
[TBL] [Abstract][Full Text] [Related]
11. Development of an adverse outcome pathway network for nephrotoxicity.
Barnes DA; Firman JW; Belfield SJ; Cronin MTD; Vinken M; Janssen MJ; Masereeuw R
Arch Toxicol; 2024 Mar; 98(3):929-942. PubMed ID: 38197913
[TBL] [Abstract][Full Text] [Related]
12. Adverse Outcome Pathway-Driven Analysis of Liver Steatosis in Vitro: A Case Study with Cyproconazole.
Luckert C; Braeuning A; de Sousa G; Durinck S; Katsanou ES; Konstantinidou P; Machera K; Milani ES; Peijnenburg AACM; Rahmani R; Rajkovic A; Rijkers D; Spyropoulou A; Stamou M; Stoopen G; Sturla S; Wollscheid B; Zucchini-Pascal N; Lampen A
Chem Res Toxicol; 2018 Aug; 31(8):784-798. PubMed ID: 29995386
[TBL] [Abstract][Full Text] [Related]
13. AOPERA: A proposed methodology and inventory of effective tools to link chemicals to adverse outcome pathways.
Rycroft TE; Foran CM; Thrash A; Cegan JC; Zollinger R; Linkov I; Perkins EJ; Garcia-Reyero N
ALTEX; 2020; 37(1):64-74. PubMed ID: 31453632
[TBL] [Abstract][Full Text] [Related]
14. Chemical-induced liver cancer: an adverse outcome pathway perspective.
Sanz-Serrano J; Callewaert E; De Boever S; Drees A; Verhoeven A; Vinken M
Expert Opin Drug Saf; 2024 Apr; 23(4):425-438. PubMed ID: 38430529
[TBL] [Abstract][Full Text] [Related]
15. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
Yamada T; Ashikaga T; Kojima H; Hirose A
Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
[TBL] [Abstract][Full Text] [Related]
16. Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.
Vinken M; Landesmann B; Goumenou M; Vinken S; Shah I; Jaeschke H; Willett C; Whelan M; Rogiers V
Toxicol Sci; 2013 Nov; 136(1):97-106. PubMed ID: 23945500
[TBL] [Abstract][Full Text] [Related]
17. Expert consultation is vital for adverse outcome pathway development: a case example of cardiovascular effects of ionizing radiation.
Chauhan V; Hamada N; Monceau V; Ebrahimian T; Adam N; Wilkins RC; Sebastian S; Patel ZS; Huff JL; Simonetto C; Iwasaki T; Kaiser JC; Salomaa S; Moertl S; Azimzadeh O
Int J Radiat Biol; 2021; 97(11):1516-1525. PubMed ID: 34402738
[TBL] [Abstract][Full Text] [Related]
18. Adverse outcome pathways: From research to regulation scientific workshop report.
Kleinstreuer NC; Sullivan K; Allen D; Edwards S; Mendrick DL; Embry M; Matheson J; Rowlands JC; Munn S; Maull E; Casey W
Regul Toxicol Pharmacol; 2016 Apr; 76():39-50. PubMed ID: 26774756
[TBL] [Abstract][Full Text] [Related]
19. The hepatotoxicity assessment of micro/nanoplastics: A preliminary study to apply the adverse outcome pathways.
Ge Y; Yang S; Zhang T; Wan X; Zhu Y; Yang F; Yin L; Pu Y; Liang G
Sci Total Environ; 2023 Dec; 902():165659. PubMed ID: 37517720
[TBL] [Abstract][Full Text] [Related]
20. AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks.
Pittman ME; Edwards SW; Ives C; Mortensen HM
Toxicol Appl Pharmacol; 2018 Mar; 343():71-83. PubMed ID: 29454060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
